Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 22.09.2019 Börsentäglich über 12.000 News von 610 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0MU8Y ISIN: ES0157097017 Ticker-Symbol: E2Z 
Frankfurt
20.09.19
08:04 Uhr
15,660 Euro
+0,030
+0,19 %
Branche
Pharma
Aktienmarkt
IBEX MEDIUM CAP
1-Jahres-Chart
ALMIRALL SA Chart 1 Jahr
5-Tage-Chart
ALMIRALL SA 5-Tage-Chart
RealtimeGeldBriefZeit
15,770
16,190
21.09.

Aktuelle News zur ALMIRALL Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
ALMIRALL Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!
MoALMIRALL, S.A.: ALMIRALL ANNOUNCES CFO LEADERSHIP TRANSITION4
29.07.Almirall's (LBTSF) CEO Peter Guenter on Half Year 2019 Results - Earnings Call Transcript5
29.07.Almirall, S.A. 2019 Q2 - Results - Earnings Call Slides4
29.07.ALMIRALL, S.A.: First semester results presentation 20196
29.07.ALMIRALL, S.A.: Almirall announces that a webcast with analysts and institutional investors will be held today ...2
25.06.Almirall hands over $50M for European rights to Dermira's Dupixent challenger5
25.06.ALMIRALL, S.A.: Presentation webcast: License Agreement of lebrikizumab for Atopic Dermatitis in Europe1
25.06.Eyeing a $500M peak sales pot, Almirall doubles down on lebrikizumab as Dermira lines up PhIII4
25.06.Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for Atopic Dermatitis63Lebrikizumab is a novel, investigational anti-IL-13 monoclonal antibody under development for the treatment of people with moderate-to-severe atopic dermatitis Dermira to receive an option exercise...
► Artikel lesen
25.06.ALMIRALL, S.A.: Almirall Exercises its Option with Dermira to License Rights to Lebrikizumab in Europe for atopic ...1
25.06.ALMIRALL, S.A.: Conference call with analysts and institutional investors: Presentation of License Agreement of ...2
17.06.ALMIRALL, S.A.: Almirall announces the re-designation of the €250,000,000 0.25 per cent. Senior Unsecured Conditionally ...3
05.06.Almirall: recent revaluation (+46%) reduces potential 13.1%9
03.06.ALMIRALL, S.A.: Almirall expects to make a decision regarding the exercise of its lebrikizumab Option by mid-year9
30.05.Prosecutors strike yet another pharma kickback settlement, this time with Almirall5
14.05.Almirall's (LBTSF) CEO Peter Guenter on Q1 2019 Results - Earnings Call Transcript6
14.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 15.05.2019 - 133FOLGENDE WERTPAPIERE WERDEN AM 14.05.2019 CUM KAPITALMASSNAHME UND AM 15.05.2019 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 14.05.2019 AND EX CAPITAL ADJUSTMENT...
► Artikel lesen
13.05.Almirall, S.A. 2019 Q1 - Results - Earnings Call Slides3
13.05.Almirall, S.A. reports Q1 results3
13.05.ALMIRALL, S.A.: Press Release Q1 2019 + Conference Call with analysts and Institutional investors5
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1